{
    "2018-06-19": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Agree To Purchase AbbVie At $55, Earn 3.2% Using Options",
                "features": {
                    "keywords": [
                        "Purchase",
                        "AbbVie",
                        "Options"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual 'Week of Possibilities'",
                "features": {
                    "keywords": [
                        "Employees",
                        "Volunteer",
                        "Week of Possibilities"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-06-22",
                "original_text": "Wired News â€“ AbbVie Presents New Undetectable Minimal Residual Disease Data from Phase-3 MURANO Trial of Venetoclax with Rituximab at 23rd European Hematology Association Annual Congress",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Phase-3",
                        "MURANO",
                        "Trial",
                        "Venetoclax",
                        "Rituximab"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-07-10",
                "original_text": "3 Great Reasons to Buy Gilead Sciences",
                "features": {
                    "keywords": [
                        "Gilead",
                        "Sciences",
                        "Buy"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-08-15",
                "original_text": "Bristol-Myers Posts Data on Empliciti, China Approves Opdivo",
                "features": {
                    "keywords": [
                        "Bristol-Myers",
                        "Empliciti",
                        "Opdivo",
                        "China",
                        "Approves"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}